»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ2003Äê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ +?[TH?2c+
rv1kIc5Za<
¿¼ÊÔ¿ÆÄ¿£ºÒ½Ñ§ÃâÒßѧ£¨»ù´¡¿Î£©¿ÆÄ¿´úÂ룺806 ej4 7'#EY
.JZoZ.FAb
Ò»Ãû´Ê½âÊÍ£¨¹²5Ì⣬ÿÌâ4·Ö£¬¹²20·Ö£© Lg[*P8wE
1.Antigen presenting cell£¨APC£© MQ5#6vJ
2.Activation induced cell death£¨AICD£© Vc$x?=
3.Chemokine
FAJ\9
4.Major histocompatibility complex£¨MHC£© Z$kff-Y4
5.immunotolerance {N[IjY
XL >Vwd
¶þÎÊ´ðÌ⣨¹²5Ì⣬ÿÌâ10·Ö£¬¹²50·Ö£© QK<sibDI
1.ÊÔÊö²ÎÓëThϸ°ûÓëBϸ°ûÏ໥¼¤»îµÄ·Ö×Ó¼°¸÷×ԵŦÄÜ a9mLPP
2.ºÎν𤸽·Ö×Ó£¿¼òÊö𤸽·Ö×ӵķÖÀ༰ÆäÔÚÃâÒßÖеÄ×÷Óà NZ/gp"D?
3.¼òÊöIIÐͳ¬Ãô·´Ó¦µÄ·¢Éú»úÖÆ SfyZ,0
4.ÔÚÕý³£Çé¿öÏ£¬ÃâÒßϵͳ¶Ô×ÔÉí¿¹Ô²»²úÉúÃâÒßÓ¦´ðµÄ»úÖÆÊÇʲô£¿ 2PE|4zG
5.±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã <s2IC_f<+
uDay||7^g
ÈýÑ¡´ðÌ⣨µÚ1Ìâ±Ø´ð£¬2ºÍ3ÌâÈÎÑ¡1Ì⣬ÿÌâ15·Ö£¬¹²30·Ö£© y/h~oGxy
1.¼òÊöÒÆÖ²ÅųⷴӦÖÐÊÜÕßTϸ°û¶ÔͬÖÖÒìÌ忹ԵÄʶ±ð»úÖÆ¡£Í¨¹ýÖ±½Óʶ±ð¼¤»îµÄÊÜÕßThϸ°ûºÍTcϸ°û·Ö±ðÔÚ¸¨ÖúÊÜÕßBϸ°ûºÍɱÉËÒÆÖ²Îï·½ÃæÓë¼ä½Óʶ±ð¼¤»îµÄThºÍTcÓкβîÒ죿Ϊʲô£¿ r#JE7uneT
2.½áºÏÄãµÄרҵÊÔÊöϸ°ûÒò×ÓÔÚ¼²²¡·¢Éú·¢Õ¹ÖеÄ×÷Óã¬Ä㽫²ÉÈ¡ÄÄЩ²ßÂÔÕë¶ÔÕâЩ°ÐµãÖÎÁƼ²²¡£¿ {'E%SIRZ)
3.ºÎΪ»ùÒò¹¤³Ì¿¹Ì壿Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹£¿ HhhN8t
S=~[ 6;G
»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ2003Äê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ M9HM:
TDs=VTd@Z
¿¼ÊÔ¿ÆÄ¿£ºÒ½Ñ§ÃâÒßѧ£¨×¨Òµ¿Î£©¿ÆÄ¿´úÂ룺906 I!dA{INN
U2
Ò»Ãû´Ê½âÊÍ£¨4·Ö/Ì⣩ H)}>&Z4
1.Antigenic determinant 0#<q]M?hW
2.IgSF IP7j)SM!
3.MBL;¾¶ LdwWB
`L
4.chemokine c [sydl
5.HLA¸´ºÏÌåµÄ¶à»ùÒòÐÔÓë¶àëÄÐÔ C=IT`iom1C
6.TCR-CD3¸´ºÏÎï >8D!K0?E
7.FADD£¨Fas-associated protein with death domain£© C$(US8:{
8.AIDS Qn(2UO!pD
9.Tumor rejection antigen 4='Xhm
10.AICD dIg/g~ t"
y^zII5|s
¶þÎÊ´ðÌ⣨15·Ö/Ì⣩ xHq"1Vs=
1.¼òÊöCD·Ö×ÓÔÚÃâÒßЧӦÖеÄ×÷Ó㨰´ÊÜÌå·ÖÀà¼òÊö£© W
@`2+}
2.¼òÊöBϸ°û²ÎÓëµÄÃâÒß¹¦ÄÜ HC(Vu
3.¼òÊö×ÔÉíÃâÒßÐÔ¼²²¡Ê±Õë¶Ô×ÔÉí×éÖ¯²úÉúÃâÒßÓ¦´ðµÄ¿ÉÄÜ»úÖÆ ug{@rt/"Z
4.ºÎνͬÖÖÒìÐÍMHC¿¹ÔÖ±½Óʶ±ðºÍ¼ä½Óʶ±ð£¿¼òÊöÆäÒì 0^$
L{V
\@;$xdA$
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å¶þÄê¹¥¶Á˶ʿÑо¿ÉúÈëѧÊÔÌâ #%N v\g;
N;4bEcWjp
@&?E3?5ll
רҵ¿Î ÃâÒßѧ k>E^FB=
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê /4/'&tY
1. Immunotoxin 2. T inducer 3. T cell receptor 4. Accessory cell pMB!I9q
5. Fc¦Å receptor 6. Cytokine 3.+TM]RYN
¶þ¡¢ ÎÊ´ðÌâ dp#JvZb
1. ÃâÒßϵͳÖУ¬ÄÄЩϸ°ûÄÜÌØÒì»ò·ÇÌØÒâÐÔµØÉ±É˰Ðϸ°û£¬ÊÔ·Ö±ð¼òÊöɱÉË×÷ÓõIJ»Í¬Ìص㡣 :B{Wf 2<z
2. ¸ù¾ÝT¡¢Bϸ°û±íÃæ±êÖ¾µÄ²»Í¬£¬¿ÉÒÔÓ¦ÓÃÄÄЩÃâÒßѧ¼¼Êõ¼ø±ðÕâÁ½Ààϸ°û£¬¼òÊöÓйصÄʵÑéÔÀí£¿ (rqc_ZU5
3. ÔÚIVÐͳ¬Ãô·´Ó¦ÖУ¬ÖÂÃôTϸ°ûÊÍ·ÅÄÄЩÁܰÍÒò×Ó²ÎÓëÃâÒßËðÉË£¬ÏêÊöÆä×÷ÓûúÀí¡£ h ` qlI1]
4. ÊÔÊöHLA¸´ºÏÌåµÄÒÅ´«Ìص㼰ÕâÐ©ÌØµãµÄÉúÎïѧÒâÒ壿 |y9(qcKn$
5. ºÎνµ¥¿Ë¡¿¹Ì壿ÏêÊöÆäÔÚ»ù´¡ÓëÁÙ´²Ò½Ñ§ÖеÄÓ¦Óᣠ-]el_:H
%"-bG'Yc
%O6r
g)$/'RB
aItQ(+y
QO2@K1Y
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÈýÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ T_R2BBT
v
'8%jA$o\g
=LXjq~p
רҵ¿Î ÃâÒßѧ GDF/0-/Z
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê pwvzs`[;
1¡¢ Complement receptor type ¢ñ 2¡¢ Serologically defined antigen M~%P1@%
3¡¢ Transfer factor 4¡¢ Immunotoxin 5¡¢ Perforin riR(CJ}Ff
6¡¢ Arthus reaction 7¡¢ Network theoty 8.Lymphocyte transformation test $ UNC0(4
9. Hybridoma technic 10.Mitogen {zX]41T
11.Dentritic cell 12.Immunoproliferation
z
h{,.c
¶þ¡¢ »Ø´ðÏÂÁÐÎÊÌâ '9{`Czc(Gb
1¡¢ ÍÌÊÉϸ°û¶Ôϸ¾úµÄÍÌÊɹý³Ì°üÀ¨ÄöÖ÷Òª½×¶Î£¬ÊÔÏêÊöÖ®¡£ nuKcq!L
2¡¢ ÊÔÊöIL-2µÄϸ°ûÀ´Ô´¹¦Äܼ°ÁÙ´²Ó¦Óᣠ5(zdM)Y7
3¡¢ Ò©Îï»ò»¯Ñ§ÊÔ¼ÁÒýÆðµÄÒ©ÕîÊôÓÚʲôÐͳ¬Ãô·´Ó¦£¬ÊÔÊöÆä»úÀí¡£ j,n\`7dD$
4¡¢ ÌåÄÚµÄÃâÒß·Ö×Ó°üÀ¨Äļ¸ÀࣿÊÔ¼òÊö¸÷ÀàÃâÒß·Ö×ÓµÄÖ÷Òª¹¦ÄÜ¡£ Sq&r
;
5¡¢ ºÎνÃâÒß±ê¼Ç¼¼Êõ£¿Ö÷ÒªÓÐÄļ¸ÀàÃâÒß±ê¼Ç¼¼Êõ£¿ÊÔ·Ö±ð¼òÊöËüÃǵÄÖ÷ÒªÔÀí¡£ r7)qr%n
k5M5bH',
M"Dv-#f
rp9?p%
0=0,ix7?#
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅËÄÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ zu3Fi= |0
Y5CDdn
6k_Uq.<X
רҵ¿Î ÃâÒßѧ xi51,y+(5
Ò»¡¢ Ãû´Ê½âÊÍ }u9#S
1¡¢ ³Ù·¢Ðͱä̬·´Ó¦Tϸ°û 2¡¢ C1ÒÖÖÆÎï w73?E#8
3¡¢ ¼¯Âä´Ì¼¤Òò×Ó 4¡¢ ¿¹ÔÌá³Ê×÷Óà V&*|%,q
5¡¢ HIAÓë¼²²¡µÄ¹ØÁª 6¡¢ Ë«¹¦ÄÜ¿¹Ìå 7¡¢ ÃâÒßÄÍÊÜ ({ O~O5k
¶þ¡¢ ÎÊ´ðÌâ rFUR9O.{E
1¡¢ TÁܰÍϸ°û¾ßÓÐÄÄЩ±íÃæ±êÖ¾£¿ÊÔÊö¸÷±íÃæ±êÖ¾µÄÉúÎïѧ×÷Óü°/»òÒâÒå¡£ i;rcgd
2¡¢ ÊÔÊöÒÆÖ²ÅųⷴӦµÄÃâÒßÓ¦´ð¹ý³Ì¼°²ÎÓëÅųⷴӦµÄÖÂÃôÁܰÍϸ°ûºÍЧӦÎïÖÊ¡£ FnKC|X
3¡¢ ºÎνϸ°ûÒò×Ó£¿¼òÊöÆä¹²Í¬Ìص㼰ÓëÁÙ´²µÄ¹ØÏµ¡£ @U3:9~Q
4¡¢ ºÎνÁܰÍϸ°ûÔÓ½»Áö¼¼Êõ£¬ÊÔÊöÆäÔÀí¼°ÒâÒå¡£ cYp/? \
5¡¢ ºÎνÉúÎïËØ-Ç׺ÍËØÏµÍ³£¿ÊÔÊöÆäÓ¦ÓÃÓÚÃâÒß±ê¼Ç¼¼ÊõµÄÔÀí£¬ÒÔABC·¨ÎªÀý˵Ã÷Ö®¡£ o%bf7)~s
2X<%BFsE
(dfC}x(3h
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÎåÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ 0SfW:3
;4U"y8PVTh
+OqEe[Wk#
רҵ¿Î ÃâÒßѧ ue^HhZ9
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê pdB\D
1¡¢ SmIg 2¡¢ Graft-versus-host reaction GVHR HKr}"`I.
3¡¢ Immunocompent cell ICC 4¡¢ Tumor-associated antigen TAA ^2H;
5¡¢ Cytokine 6¡¢ Immune tolerance 7¡¢ Biological responsw modifier BRM *
|<T@BXn
¶þ¡¢ ÎÊ´ðÌâ (i L*1f
1¡¢ ÃâÒßϵͳÄÚÆðɱÉËЧӦµÄϸ°ûÓÐÄÄЩ£¿ÊÔ¼òÊöÆäɱÉËЧӦµÄÌØµã¡£
99.F'Gz
2¡¢ ºÎν¿¹ÌåµÄ¶àÑùÐÔ£¿¿¹ÌåµÄ¶àÑùÐÔ±íÏÖÔÚÄÄЩ·½Ã棿¼òÊö²úÉú¿¹Ìå¶àÑùÐÔµÄÔÀí¡£ Jz=|-F(Sy
3¡¢ ÊÔÊö¢òÐÍÓë¢óÐͳ¬Ãô·´Ó¦·¢Éú»úÖÆµÄÒìͬµã¡£ .XqeO@z
4¡¢ ºÎνMHC£¿ÊÔ¼òÊöÆä¹¦ÄÜ¡£ }K8e(i6z
5¡¢ ºÎνÃâÒß±ê¼Ç¼¼Êõ£¿Ö÷ÒªÓÐÄļ¸ÀàÃâÒß±ê¼Ç¼¼Êõ£¬ÒÔø±ê¼Ç¼¼ÊõΪÀý¼òÊöÆäÖ÷ÒªÔÀí¡£ Um}AV
K-~g IlbQ`
j g//I<D
]Zt ]wnL+
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÁùÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ PWZd<
4e/!BGkAS
d&CpaOSu
רҵ¿Î ÃâÒßѧ gyD ;kn\CP
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê 2,dWD<h
1. IgSF 2. Fc 3. Flow cytometry 4. Adhesion molecule ~uH_y-
5. Autogous mixed lymphoyte reaction Cdib{y<ji
¶þ¡¢ ÎÊ´ðÌâ m3BL
1. ÊÔÊöÍâÀ´TD¿¹Ô½øÈë»úÌåÓÕµ¼¿¹Ìå²úÉúµÄÈ«¹ý³Ì¡£ |ZE^'e*k
2. ºÎνϸ°ûÒò×Ó£¿¼òÊöIL-2µÄ¼ì²â·½·¨¼°ÆäÔÀí¡£ a/\{NHs6"5
3. ¼òÊö¿¹¶ÀÌØÐÍÍøÂçµÄµ÷¿Ø×÷Óᣠ.=9WY_@SZ
4. ÃâÒßÓ¦´ð¶Ô»úÌåÓкÎÀûº¦¹ØÏµ£¿ DrKB;6
'Gqv`rq&
h#"$W
;(
>9rZVNMU
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÆßÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ 6_4B!
n'v\2(&uYN
Ac|\~w[\
רҵ¿Î ÃâÒßѧ nV7Vc;
Mn(iAsg
k1q/L|')
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê 6ki2/ Q
1. Idiotupe 2. Opsonization 3. Epitope 4. Immunologic tolerance 5K ;E*s,
5. Delayed type hypersensitivity [K.1 X=O}
¶þ¡¢ ÎÊ´ðÌâ 4lB??`UN
1. ÊÔÊö²¹Ì徵伤»î;¾¶ÓëÅÔ·¼¤»î;¾¶µÄÒìͬ¡£ VwE4:/7YN
2. ¼òÊö¿¹ÌåµÄ»ù±¾½á¹¹£¨ÒÔIgGΪÀý£©Ó빦ÄÜ¡£ M/quswn1
3. ¼òÊöHLAÓëҽѧµÄ¹ØÏµ¡£ #dj?^n g
4. ÊÔÊöµ¥ºË/¾ÞÊÉϸ°ûÔÚÃâÒßÓ¦´ðÖеÄ×÷ÓᣠZtg_='n
5. ¼òÊöÃâÒßÓ¦´ðÖи÷ÖÖÀàÐ͵Äϸ°û¶¾×÷ÓᣠHa `N
2Qp}f^
)&c#?wx'w
L"|Bm{Run
o=3hWbe
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å°ËÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ 3$nK
^PTf8o
Z5>~l
רҵ¿Î ÃâÒßѧ 0cq@lT6
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê R
J{$`
d
1. hypersensitivity 2. cluster of differentiation ;Zd_2
CZ
3. adhesion molecules 4. supper antigen 5. split tolerance +:.Jl:fx4
¶þ¡¢ ÎÊ´ðÌâ e{5?+6KH
1. ºÎνϸ°ûÒò×Ó£¿ÊÔÊöϸ°ûÒò×ÓµÄÖ÷ÒªÉúÎïѧ»îÐÔ¡£ qh~bX
i!
2. ¼òÊöMHC¿¹ÔµÄ·Ö×ӽṹ¼°Æä×éÖ¯·Ö²¼¡£ D=-}&w_T"
3. ÊÔÊöÐØÏÙÒÀÀµÐÔ¿¹ÔÒýÆðÌåÒºÃâÒßÓ¦´ðµÄÈ«¹ý³Ì£¨°üÀ¨³õ´ÎÃâÒßÓ¦´ðºÍÔÙ´ÎÃâÒßÓ¦´ð£©¡£ Io]FDPN
4. Ϊʲô˵²¹Ì弤»î;¾¶Ö÷Òª²ÎÓëÌìÈ»ÃâÒߣ¿ÊÔÊö²¹ÌåÊÇÈçºÎ¾¹ýÅÔ·;¾¶¶ø±»¼¤»îµÄ¡£ wQ/* f9
5. Ϊʲô¿¹Ä³Ò»Ï¸°ûÒò×ÓÊÜÌåµÄµ¥¿Ë¡¿¹ÔÌ壬ÓбíÏÖ³öÊÜÌå·â±Õ×÷Ó㬶øÓеÄÔò±íÏÖ³öÊÜÌå´Ì¼¤×÷Óã¿ X
."z+-eh
'q-q4QCB
z%YNZ^d
,x8;| o5
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å¾ÅÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ
vmqa_gU\
רҵ¿Î ÃâÒßѧ ~?F,kmO}?
Ò»¡¢ Ãû´Ê½âÊÍ 8%7%[WC#
1. ¿¹ÔÐÔ 2. ÃâÒßÇòµ°°×³¬¼Ò×å 3. ¶ÀÌØÐÍ 4. ¿¹Ô¾ö¶¨×å _6NUtU
5. GVHR }csA|cC
¶þ¡¢ ÎÊ´ðÌâ UphTMyn3
1. Á½ÖÖ²¹Ì弤»î;¾¶µÄµ÷½ÚÒò×ÓÓÐÄÄЩ£¿±È½ÏËüÃÇÁ½ÖÖ;¾¶ÖеÄ×÷ÓᣠJN0h3nZ_
2. ¢òÐͳ¬Ãô·´Ó¦µÄ»úÀíÌØµãÊÇʲô£¿¾Ù³öÈý¸ö¢òÐͳ¬Ãô·´Ó¦µÄÀý×Ó¡£ ;5 j|B|v
3. ÊÔÊöϸ°ûÒò×ÓµÄ×÷ÓÃÌØµã¡£ /MF
7ZvN.
4. Bcell½éµ¼µÄÌåÒºÃâÒßÓ¦´ðµÄ¹ý³Ì¡£ c@t?R$c
5. MPSµÄÃâÒßѧ¹¦ÄÜ¡£ #d-({blo<
~rb0G*R>
X.fVbePxUU
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å¾ÅÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ PftK>,+,
PM\Ju]
PJ.\)oP
רҵ¿Î ÃâÒßѧ 9F/I",EA
Ò»¡¢Ãû´Ê½âÊÍ kTb$lLG\xk
1. ÃâÒßÇòµ°°×µÄ¶ÀÌØÐÍ 2. 𤸽·Ö×Ó 3. ÃâÒßÇòµ°°×³¬¼Ò×å :;+!ID_
4. ¸ÉÈÅËØ 5. HLAµÄ¶à̬ÐÔ 6. ÐØÏÙÒÀÀµÐÔ¿¹Ô 7. ÃâÒßÄÍÊÜ ~:a1ELqVw
8. ËÙ·¢Ðͳ¬Ãô·´Ó¦ 9. µ¥¿Ë¡¿¹Ìå 10. ²¹Ì徵伤»î;¾¶ iq; |
i!
11. »ìºÏÁܰÍϸ°û·´Ó¦ 12. ÓÐË¿·ÖÁÑ Mn0.!J
"
Èý¡¢ ÎÊ´ðÌâ pbVL|\oB}
1. ÊÔ¼òÊö¾ÞÊÉϸ°ûÌá³ÊTD¿¹ÔµÄ¹ý³Ì¡£ *()['c#CC
2. ÊÔ¼òÊöÒÆÖ²ÎËÞÖ÷·´Ó¦µÄ·¢Éú»úÖÆ ^Oz~T|)
3. ÊÔÊö²¹ÌåµÄÖ÷ÒªÉúÎïѧ×÷Óà V:n0BlZ,B
4. ÒÔIgGΪÀý£¬ÊÔÊöÃâÒßÇòµ°°×·Ö×ӵĻù±¾½á¹¹ 0?7yM:!l
5. ÊÔÊöTϸ°ûµÄÖ÷Òª±íÃæ±êÖ¾¼°¹¦ÄÜ <]rayUyaf
#1<m\z 7l
[b++bCH3
.|,LBc!
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å¾ÅÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ >]h{[kU %4
:U?g']`Z##
b'z
$S+
רҵ¿Î ÃâÒßѧ WyO*8b_
D
Ò»¡¢Ãû´Ê½âÊÍ 7[
m+r:y
1. Ig¶ÀÌØÐÍ 2. SAg 3. 𤸽·Ö×Ó 4. CSF 5. IgSF 6. Tϸ°û»î»¯µÄ´Ì¼¤·Ö×Ó j
3<Ci {3
7. HLAÓë¼²²¡µÄ¹ØÁª 8. ELISA 9. ÁܰÍϸ°ûµÄ±íÃæ±êÖ¾ !l
'n
X
Èý¡¢ ÎÊ´ðÌâ EG{+Sz
1. ¼òÊöTÁܰÍϸ°ûµÄ·ÖÀ༰¹¦ÄÜ£¿ uKJ:)oyaCP
2. ¼òÊöHLAÍ»±äÌåµÄ»ùÒò×é³É¼°HLAµÄ¹¦ÄÜ£¿ K"!rj.Da
3. ¼òÊö»úÌå¶ÔÍâÔ´ÐÔ¿¹Ô£¨ÒìÎԣ©µÄ´¦Àí£¬ÈçIgÌá³Ê¹ý³Ì£¿ 9)!Ksg(h
4. ¼òÊö²¹ÌåÁ½ÖÖ¼¤»î;¾¶µÄ»ù±¾¹ý³Ì£¬²¢±È½Ï¶þÕßÒìͬ£¿ xQFRM aQE
5. ¼òÊöAIDSÖÐCD4+ϸ°û¼õÉٵĻúÖÆ£¿ ?{J1&;j*
ZdW+=;/#
o-<i+ To%
db )2>
6qZQ20h
99Äê˶ʿÑо¿ÉúÃâÒßѧÊÔÌâ ioi/`iQR
Ò»¡¢Ãû´Ê½âÊÍ ) 57'<
2¡¢ HLAµÄ¶à̬ÐÔ 3¡¢ 𤸽·Ö×Ó 4¡¢ ¶ÀÌØÐÍ 5¡¢ ¿¹ÔëÄתÔËÎï st w@@GQ
6¡¢ Ig³¬¼Ò×å 7¡¢ µòÍö 8¡¢ ÓÐË¿·ÖÁÑÔ 9¡¢ CD4·Ö×Ó QytO0K5
10¡¢ ³¬Ãô·´Ó¦ 11¡¢ ×ÔÉíÃâÒß²¡ h[(YH ;Y
¶þ¡¢ ÎÊ´ðÌâ IjhRSrCv
1¡¢ ÊÔÊöÍâÔ´ÐÔ¿¹ÔºÍÄÚÔ´ÐÔ¿¹ÔÌá³ÊµÄ¹ý³Ì¡£ ZcA"HD%
2¡¢ ÊÔÊöBϸ°û½éµ¼µÄÔÙ´ÎÃâÒßÓ¦´ðµÄ¹ý³Ì¡£ amsl>wc!
3¡¢ ÊÔÊö·Ö×ÓˮƽµÄÃâÒßµ÷½Ú¡£ qZ<n\Mt
4¡¢ ÊÔÊö»ñµÃÐÔÃâÒßȱÏÝ×ÛºÏÕ÷£¨AIDS£©µÄ·¢²¡»úÖÆ¡£ KDN#CU
whI4@#
2000Äê˶ʿÑо¿ÉúÃâÒßѧÊÔÌâ ,88B@a
Ò»¡¢ Ãû´Ê½âÊÍ I]ej ]46K
1¡¢ µ÷Àí×÷Óà 2¡¢ 𤸽·Ö×Ó 3¡¢ ³¬¿¹Ô 4¡¢ ÃâÒßȱÏݲ¡ N<#J!0w
5¡¢ FasÓëFasL 6¡¢ µ¥¿Ë¡¿¹Ìå 7¡¢ ÃâÒßÄÍÊÜ XU'(^Y8Imz
8¡¢ ÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£© 9¡¢ Ö×ÁöÏà¹Ø¿¹Ô£¨TAA£© 2?,lr2
10¡¢ ÒõÐÔÑ¡Ôñ J.~@j;[2
¶þ¡¢ ÎÊ´ðÌâ "|6(.S+o
1¡¢ ºÎνϸ°ûÒò×Ó£¿ÊÔÊöϸ°ûÒò×ӵĹ²Í¬Ìص㣿 8mr fs%_
2¡¢ ºÎνAPC¼°ÆäÖÖÀࣿ¼òÊöÍâÔ´ÐÔ¿¹ÔµÄÈÜøÌåÌá³Ê;¾¶£¿ &wNr2PHd#
3¡¢ ¼òÊöϸ°ûÃâÒßÓ¦´ðµÄÁ½ÀàЧӦϸ°ûµÄЧӦ»úÖÆ£¿Ï¸°ûÃâÒßµÄÉúÎïѧÒâÒ壿 C5=^cH8
4¡¢ ºÎνMHC£¿¼òÊöMHCµÄ¹¦ÄÜ£¿ t(}Y /'
5¡¢ ºÎν×ÔÉíÃâÒß²¡£¿¼òÊö×ÔÉíÃâÒß²¡µÄ×éÖ¯ËðÉË»úÖÆ£¿. 2K~v`c*4
P#pb48^-
ygTfQtN
.UxkTads
ͬ¼ÃÒ½¿Æ´óѧ2000Äê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ DvW
Bvs,
<,Gjo]z
S> Fb'rJ3
רҵ¿Î ÃâÒßѧ hbXm Ist
Ò»¡¢½«ÏÂÁÐÓ¢Óïµ¥´Ê·Òë³ÉÖÐÎIJ¢Ãû´Ê½âÊÍ n_sV>$f-u
1. Cytokines 2. adhesion molecules 3. graft versus host reaction X>dQK4!R
4. immunologic tolerance 5. Opsonization Xk:x=4u&
Èý¡¢ ÎÊ´ðÌâ jhT/}"v
1. ʲôÊÇMHC£¿ÊÔÊöMHC-¢òÀà·Ö×ӵĽṹ¡¢¸÷²¿Î»¹¦ÄÜ£¬MHC-¢òÀà·Ö×ÓµÄ×éÖ¯·Ö²¼¼°ÆäÃâÒßѧ×÷ÓᣠTu:lIy~A
2. ÓÐÄÄÈý´ú¿¹Ì壿ÊÔÊö¿¹Ì壨IgG£©µÄ»ù±¾½á¹¹¡¢¸÷²¿Î»¹¦Äܼ°ÕâÈý´ú¿¹ÌåµÄÌØÐÔ¡£ qPu?rU{2
3. ʲôÊÇ×ÔÉíÃâÒß²¡£¿ÊÔÊöÆä·¢²¡»úÖÆ¡£ .9DhD=8aIO
4. ÃâÒßϵͳɱÉ˰Ðϸ°ûµÄ·½Ê½¼°ÏàӦϸ°ûºÍ·Ö×ÓÓÐÄÄЩ£¿ÊÔÊöTc½éµ¼µÄϸ°ûÃâÒßÓ¦´ð¡£ J;fbE8x
5. »úÌåµÄÃâÒßϵͳΪʲô¿ÉÒÔʶ±ð×Ô¼ººÍÒ켺£¿ÆäÖ÷Òª»úÖÆÊÇʲô£¿ dnANlNMk?
*h?*RUQ
B4OFhtYE
=
CXX.%N
"<oR.f=0
:hHKm|1FE
»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ
i[/1AI
o/U}G,|G
be6`Sv"H
2001ÄêÕÐÊÕ˶ʿÑо¿ÉúÈëѧרҵ¿Î¿¼ÊÔÊÔÌâ <{V{
2V#
¿¼ÊÔ¿ÆÄ¿£ºÒ½Ñ§ÃâÒßѧ $SLyI$<gP
Ò»¡¢ ½âÊÍÏÂÁÐÃû´Ê Mt4`~`6
1. C3b½éµ¼µÄµ÷Àí×÷Óà 2.Tϸ°û¼¤»îµÄµÚ¶þÐźÅ3.Th1ϸ°û 4.HLAµÄ¶à̬ÐÔ ,[n=PJVw/
5.C1ÒÖÖÆÎï 6.TCR¦Ã¦ÄTϸ°û7.³Ù·¢Ðͳ¬Ãô·´Ó¦ 8.Ç÷»¯ÐÔϸ°ûÒò×Ó9.ÃâÒßÇòµ°°×µÄÀà±ðת»¯ 10.ÔìѪ¸Éϸ°û .j!:Hp(z}
11.»î»¯ÓÕµ¼µÄϸ°ûËÀÍö +5ql`C
¶þ¡¢ Çë»Ø´ðÏÂÁÐÎÊ´ð nQw, /Lk
1. ºÎνµ¥¿Ë¡¿¹Ì壬¼òÊöÆäÖÆ±¸ÔÀí¡£ AWZ4h,as{
2. ¼òÊöTϸ°ûÔÚÐØÏÙÄڵķ¢Óý¹ý³Ì¡£ ZB}zT9JaE
3. ÃâÒßϸ°û±íÃæÖ÷ÒªÓÐÄļ¸Àà±íÃæ¿¹ÔºÍ±íÃæÊÜÌ壬¼òÊö¸÷Àà·Ö×ÓµÄÖ÷Òª¹¦ÄÜ¡££¨HLA¡¢CD¡¢AM¡¢CKR¡¢CR¡¢MitogenR¡¢TCR¡¢BCR¡¢FcR£© WAr6Dv,8
4. ÊԱȽÏTCR¸´ºÏÌåºÍBCR¸´ºÏÌå½á¹¹Ó빦ÄܵÄÒìͬ¡£ -P]onD
5. ÊԱȽϳ¬¿¹ÔÓëÆÕͨ¿¹ÔµÄÒìͬ¡£ -OQ6;A"#
e~G IUwJ
;S2/n$Ju_
!;PKx]/&
f<DqA/$
\p iz Vt
»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ `?"[u"*
2001ÄêÕÐÊÕ˶ʿÑо¿ÉúÈëѧµ¥¶À¿¼ÊÔÊÔÌâ Nrp1`qY
¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ jW|M)[KJN
uY)|
Ò»¡¢ Ãû´Ê½âÊÍ 62OZj%CXN
1. ¿¹Ô³ÊµÝ 2. µ÷Àí×÷Óà 3. ³Áµí·´Ó¦ 4. ×ÔÉíÃâÒß cZ/VMQEr
5. GVHR 6. ÔìѪ¸Éϸ°û 7. ¿Ë¡ѡÔñѧ˵ 8. Ir»ùÒò 4H%Ai(F}_
9. ³¬Ãô·´Ó¦ 10. ³¬¿¹Ô &C E){jC
¶þ¡¢ÎÊ´ðÌâ ADZ
U?7)
11. ¼òÊö²¹ÌåµÄÅÔ·¼¤»î;¾¶ ]+78
"(
12. ¼òÊöT¡¢Bϸ°ûÌØÕ÷µÄ²îÒì )e\IdKl=
13. ¼òÊöT¡¢Bϸ°û¿¹Ô¾ö¶¨´ØµÄ²îÒì _E[)_yH'-
14. ΪʲôÃâÒßÇòµ°°×¾ßÓп¹ÔÐÔ£¿ÊÔÊöÃâÒßÇòµ°°×µÄ¿¹ÔÐÔ¡£ LT '2446
15. ʲôÊÇÖ×Áö¿¹Ô£¿ÊÔÊö»úÌåÕë¶ÔÖ×Áö¿¹Ô²úÉú¿¹Ö×ÁöÃâÒßÓ¦´ðµÄ»úÖÆ¡£ 2G`tS=Un
X[iQ%Y$/n